CNCR vs. PBPH

Last updated Jun 4, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and PBPH (Portfolio Building Block World Pharma and Biotech Index ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while PBPH tracks the BITA Global Pharma and Biotech Select Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.13%/yr for PBPH.

Performance

CNCR vs. PBPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Portfolio Building Block World Pharma and Biotech Index ETF (PBPH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

PBPH

• 1D: 0.58%
• 1M: 0.07%
• YTD: -1.13%
• 6M: -0.02%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. PBPH - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
PBPH Portfolio Building Block World Pharma and Biotech Index ETF	-7.48%

Return for Risk

CNCR vs. PBPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Portfolio Building Block World Pharma and Biotech Index ETF (PBPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	PBPH	Difference
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.04	—

Drawdowns

CNCR vs. PBPH - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum PBPH drawdown of -11.10%. Use the drawdown chart below to compare losses from any high point for CNCR and PBPH.

Drawdown Indicators

	CNCR	PBPH	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-11.10%	+11.10%
Current Drawdown Current decline from peak	0.00%	-8.69%	+8.69%
Average Drawdown Average peak-to-trough decline	0.00%	-4.23%	+4.23%

Volatility

Volatility by Period

	CNCR	PBPH	Difference
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	16.78%	-16.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	16.78%	-16.78%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	16.78%	-16.78%

CNCR vs. PBPH - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than PBPH's 0.13% expense ratio.

Dividends

CNCR vs. PBPH - Dividend Comparison

CNCR has not paid dividends to shareholders, while PBPH's dividend yield for the trailing twelve months is around 0.09%.

Position	TTM	2025
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%
PBPH Portfolio Building Block World Pharma and Biotech Index ETF	0.09%	0.09%

Frequently Asked Questions

Which ETF is better, CNCR or PBPH?

On fees, PBPH is cheaper at 0.13% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or PBPH?

PBPH is cheaper with a 0.13% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or PBPH?

PBPH has the higher dividend yield at 0.09%, compared with 0.00% for CNCR.

What is the main difference between CNCR and PBPH?

CNCR tracks Loncar Cancer Immunotherapy Index, while PBPH tracks BITA Global Pharma and Biotech Select Index. They also come from different issuers: Exchange Traded Concepts and Portfolio Building Block. Their fees differ too: 0.79% for CNCR and 0.13% for PBPH.